Investors have been flocking to biotech stocks this year, with the IBB, the ETF that tracks biotech stocks, making noteworthy gains. So far in 2015, several industries have either underperformed or provided mixed results, leading to a rather ho-hum showpiece for U.S. blue-chip indices.Biotech stocks, on the other hand, have consistently returned positive results in the markets over the past […]
Many individual investors have opted to invest in biotech ETFs and mutual funds. The XBI and SBIO funds have performed well because they focus more on small and mid-sized biotech companies. The IBB, which has emerged as something of a proxy for the industry for many investors, is weighted much more heavily to bigger, more proven biotech companies.The volatility of […]
Inovio Pharmaceuticals (NASDAQ:INO)On August 10, 2015 shares of Inovio were up about 25% after the company announced a partnership deal with a big pharmaceutical company known as AstraZeneca (NYSE:AZN). Although one key thing to note here is that this deal is being established with MedImmune specifically, but it is the research and development arm for AstraZeneca. With this deal established AstraZeneca […]
They say good things come in threes. If so, biotech companies could be in for not just another year of outperformance, but another decade. The first era of biotech was a building phase, when companies created their first blockbuster drugs. The second, current one, has resulted in a four-year rally that reflects the sector’s transition from a cluster of one-hit […]
Harness Biotech Stock Volatility with an Options StrategyCompanies / BioTechAug 13, 2015 – 10:27 PM GMTBy: TLSReportVolatility is the nature of the biotech beast, and it must be tamed or utilized to advantage. That’s the philosophy of Eden Rahim, portfolio manager and option strategist at Theta Strategies Capital. Can you grow a portfolio if some of your more successful names […]
Related ICPTCNBC’s Meg Tirrel Speculates About Gilead’s New AcquisitonHow Wedbush’s Liana Moussatos Is Trading These Biopharma StocksShaken, Not Stirred: Is The ‘Biotech Bubble’ Beginning To Burst?(Seeking Alpha)Related Sarepta Therapeutics Announces New England Journal of Medicine Publication of Phase I Clinical Data of Marburg Drug Candidate, AVI-7288, Supporting Safety of the PMOplus® platformShort-Sellers Betting Against These BiotechsSarepta Posts Narrower-than-Expected Loss in […]
Several major biotech companies like Biogen (BIIB – Analyst Report), AbbVie (ABBV – Analyst Report), Celgene and Gilead reported second quarter results over the last five trading days. Biogen has been grabbing headlines for the wrong reasons – although the company’s earnings were better-than-expected, revenues missed expectations.With the company saying that it is cutting its outlook based on revised expectations […]
This article first appeared on Inc.com posted from Peter Economy.I have spent my career in the investment business and have participated in thousands of meetings or calls with managements of public companies. A few times, I have received inside information, and I guarantee that you know when you’ve got it. When I worked at a large mutual fund company, we […]
Ishares Nasdaq Biotechnology Index (IBB) has been on a tear in the last year, outperforming the NASDAQ and S&P 500 by multiples greater than 3x and 6x, respectively. This rapid appreciation has spurted chatter of a bubble forming in the biotech sector. Even US leaders have expressed a difference of opinion. Yellen, for example, stated back in July 2014 that the biotech industry […]
Some traders like to gamble on big news events that could have a dramatic effect on a particular stock. For example, the release of a company’s earnings report could cause an underlying stock to jump to new highs or drop to significant lows. While this may not interest all investors, it does prove to be a point of intrigue for […]
